Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-03-03
1999-02-09
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 63, 5142282, 5142352, 514255, 544 61, 544 69, 544127, 544229, 544362, 546 14, 546135, 546137, A61K 3144, A61K 31435, C07D45302, C07D40100
Patent
active
058694994
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This application is the U.S. national phase of PCT Patent Application PCT/JP94/01092, which was filed in the Japanese Receiving Office on Jul. 5, 1994.
This invention relates to novel and useful benzyloxyquinuclidines of interest to those in the field of medical chemistry and chemotherapy. More particularly, it is concerned with a novel series of benzyloxyquinuclidines, including their pharmaceutically acceptable salts and pharmaceutical composition thereof, which are of special value in view of their ability to antagonize substance P (SP). In this way, these compounds are of use in treating gastrointestinal disorders, central nervous system disorders, allergy, inflammatory diseases, asthma, pain, migraine, emesis, urinary incontinence and angiogenesis in mammalia.
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specially, substance P is a pharmaceutically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Pat. No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine (see B. E. B. Sandberg et al., J. Med. Chem., 25, 1009 (1982)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders and diseases of GI tract, like ulcerative colitis and Crohn's diseases, etc (see D. Regoli in "Trends in Cluster Headache" edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, 1987, PP. 85-95).
It is reported that the tachykinin antagonists are useful for allergic conditions (Hamelet et al., Can. J. Pharmacol. Physiol., 66, 1361, 1988), immunoregulation (Lotz et al., Science, 241, 1218, 1988; and Kimball et al., 3. Immunol., 141, 3564, 1988), vasodilation, bronchospasm, reflex or neuronal control of the viscera (Mantyh et al., PNAS, 85, 3235, 1988) and senile dementia of the Alzheimer type (Yankner et al., Science, 250, 279, 1990). Recently the efficacy of the substance P antagonists for the treatment of emesis (EP 0533280 A) and the relationship between substance P antagonists and sunburn (F. Gillardon et al, Involvement of neuropeptides and nitric oxide in the sunburn reaction following cutaneous ultraviolet irradiation. abstract 129, 1993, 5th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, 1993, Geneva) are discussed.
In the recent past, some attempts to develop the tachykinin antagonist such as substance P have been carried out for the purpose of the treatment of the above disorders or diseases (John A Lowe, III, et al., Drugs of the Future, 17(12), 1115, 1992).
JP Kokai No. 78354/93 (EP-0499313A1) discloses a wide variety of azabicyclic compounds as tachykinin antagonists such as substance P antagonists, including a number of quinuclidine compounds having diarylmethyl and benzyloxy substituents. However, none of the individual compounds described in JP Kokai No. 78354/93 (EP-0499313A1) is a 6-diarylmethyl-5-benzyloxyquinuclidine having an additional substituent at the 2- or 3- position.
The purpose of the present invention is to provide the novel benzyloxyquinuclidines with substance P antagonistic activities. In addition, the purpose of the invention is also to provide a composition, which includes a benzyloxyquinuclidine as an active ingredient, in treating of gastrointestinal disorders, central nervous system disorders, allergy, inflammatory diseases, asthma, pain, migraine or emesis in mammalia, especially humans.
BRIEF DISCLOSURE OF THE INVENTION
The inventors made an effort in or
REFERENCES:
patent: 5242930 (1993-09-01), Baker et al.
patent: 5607946 (1997-03-01), Kulagowski et al.
patent: 5620971 (1997-04-01), Armistead et al.
patent: 5620972 (1997-04-01), Van Niel
patent: 5620976 (1997-04-01), Sugimoto et al.
patent: 5620981 (1997-04-01), Blankley et al.
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5621000 (1997-04-01), Arena et al.
patent: 5621004 (1997-04-01), Dunn et al.
patent: 5621140 (1997-04-01), Schloemer et al.
patent: 5622236 (1997-04-01), Azumi et al.
patent: 5622947 (1997-04-01), Ogawa et al.
patent: 5622950 (1997-04-01), Baker et al.
patent: 5622976 (1997-04-01), Takasugi et al.
patent: 5622980 (1997-04-01), Caldwell et al.
patent: 5622982 (1997-04-01), Schuster et al.
patent: 5622983 (1997-04-01), Horwell et al.
patent: 5622985 (1997-04-01), Olukotun et al.
patent: 5622990 (1997-04-01), Katdare et al.
Cascieri et al., Characterization of the Interaction of N-Acyl-Tryptophan Benzyl Ester Neurokinin Antagonists with the Human Neurokinin-1 Receptor, The Journal of Biological Chemistry, vol.269, No. 9, pp. 6587-6591, Mar. 4, 1994.
MacLeod et al., N-Acyl-tryptophan Benzyl Esters: Potent Substance P Receptor Antagonists, Journal of Medicinal Chemistry, vol. 36, No. 14, pp. 2044-2045, Jul. 9, 1993.
Satake Kunio
Wakabayashi Hiroaki
Coleman Brenda
Ginsburg Paul H.
Pfizer Inc
Richardson Peter C.
Shah Mukund J.
LandOfFree
Benzyloxyquinuclidines as substance P antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzyloxyquinuclidines as substance P antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzyloxyquinuclidines as substance P antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1948645